To our knowledge, GZD824 is the first compound to show an antitumor effect in pre-B ALL by inhibiting both the SRC kinase and IRS1/PI3K/AKT pathways (Figure 7). The gene discussed is AKT1; the disease is acute lymphoblastic leukemia.